Multiple-dose study to examine safety, tolerability, pharmacokinetics, and pharmacodynamics of LY2148568 long-acting release in Japanese patients with type 2 diabetes mellitus.
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2014
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 10 Jun 2017 Biomarkers information updated
- 16 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Aug 2010 Actual end date (May 2008) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History